$ABUS
Arbutus Biopharma Corp Stock $abus

$abus Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-Q Financial Statement

#000144702819000071 Filed on November 06, 2019

Income Statement

Concept	2019 Q4	2019 Q3	2019 Q1
Revenue	$1.618M	$3.061M	$679.0K
YoY Change	-3.58%	92.88%	-52.72%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.880M	$3.250M	$4.410M
YoY Change	-68.3%	23.57%	20.16%
% of Gross Profit
Research & Development	$12.42M	$17.73M	$14.71M
YoY Change	12.3%	7.03%	5.47%
% of Gross Profit
Depreciation & Amortization	$510.0K	$507.0K	$509.0K
YoY Change	2.0%	2.01%	-15.45%
% of Gross Profit
Operating Expenses	$14.80M	$94.09M	$19.88M
YoY Change	-15.43%	176.62%	0.17%
Operating Profit	-$13.09M	-$91.03M	-$19.20M
YoY Change	-22.58%	180.72%	4.3%
Interest Expense	-$11.57M	$1.100M	$12.00K
YoY Change	386.13%		-88.46%
% of Operating Profit
Other Income/Expense, Net		-$4.134M	-$4.055M
YoY Change		-212.61%	-515.47%
Pretax Income	-$24.65M	-$95.16M	-$23.25M
YoY Change	35.07%	230.93%	33.4%
Income Tax	$0.00	-$12.66M	$0.00
% Of Pretax Income
Net Earnings	-$24.65M	-$82.50M	-$23.25M
YoY Change	35.1%	237.12%	33.4%
Net Earnings / Revenue	-1523.73%	-2695.3%	-3424.3%
Basic Earnings Per Share	-$0.46	-$1.50	-$0.47
Diluted Earnings Per Share	-$418.0K	-$1.451M	-$417.1K
COMMON SHARES
Basic Shares Outstanding	56.85M shares	56.85M shares	56.12M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2019 Q3	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$90.83M	$90.10M	$110.6M
YoY Change	-27.1%	-36.55%	-35.88%
Cash & Equivalents	$31.80M	$90.08M	$83.97M
Short-Term Investments	$59.04M	$0.00	$26.60M
Other Short-Term Assets	$1.800M	$1.800M	$700.0K
YoY Change	-35.71%	63.64%	-53.33%
Inventory
Prepaid Expenses
Receivables	$1.204M	$2.488M	$923.0K
Other Receivables	$0.00	$0.00	$300.0K
Total Short-Term Assets	$93.83M	$94.34M	$112.5M
YoY Change	-27.39%	-34.5%	-35.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$8.676M	$9.150M	$9.667M
YoY Change	-14.48%	-12.2%	-18.28%
Goodwill	$0.00	$0.00	$22.47M
YoY Change	-100.0%	-100.0%	-7.77%
Intangibles	$0.00	$0.00	$43.84M
YoY Change	-100.0%	-100.0%	-25.25%
Long-Term Investments	$0.00	$10.97M	$17.68M
YoY Change	-100.0%	-55.53%
Other Assets	$293.0K
YoY Change
Total Long-Term Assets	$11.71M	$22.94M	$96.73M
YoY Change	-88.14%	-77.38%	1.99%
TOTAL ASSETS
Total Short-Term Assets	$93.83M	$94.34M	$112.5M
Total Long-Term Assets	$11.71M	$22.94M	$96.73M
Total Assets	$105.5M	$117.3M	$209.2M
YoY Change	-53.69%	-52.21%	-22.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.400M	$1.400M	$2.300M
YoY Change	-25.0%	-54.84%	155.56%
Accrued Expenses	$5.200M	$7.300M	$6.100M
YoY Change	-31.58%	17.74%	-4.69%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.828M	$8.817M	$8.823M
YoY Change	-30.35%	-30.4%	-15.13%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$25.00M	$24.80M	$6.500M
YoY Change	557.89%	416.67%	-36.89%
Total Long-Term Liabilities	$25.00M	$24.80M	$6.500M
YoY Change	557.89%	416.67%	-36.89%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.828M	$8.817M	$8.823M
Total Long-Term Liabilities	$25.00M	$24.80M	$6.500M
Total Liabilities	$32.79M	$33.64M	$28.01M
YoY Change	18.5%	11.59%	-25.53%
SHAREHOLDERS EQUITY
Retained Earnings	-$970.1M	-$942.6M	-$831.2M
YoY Change	20.48%	20.17%	9.68%
Common Stock	$898.5M	$884.6M	$882.1M
YoY Change	2.18%	0.66%	0.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$72.74M	$83.64M	$181.2M
YoY Change
Total Liabilities & Shareholders Equity	$105.5M	$117.3M	$209.2M
YoY Change	-53.69%	-52.21%	-22.52%

Cashflow Statement

Concept	2019 Q4	2019 Q3	2019 Q1
OPERATING ACTIVITIES
Net Income	-$24.65M	-$82.50M	-$23.25M
YoY Change	35.1%	237.12%	33.4%
Depreciation, Depletion And Amortization	$510.0K	$507.0K	$509.0K
YoY Change	2.0%	2.01%	-15.45%
Cash From Operating Activities	-$13.35M	-$23.47M	-$16.58M
YoY Change	-21.84%	77.75%	-16.96%
INVESTING ACTIVITIES
Capital Expenditures	-$60.00K	$255.0K	$31.00K
YoY Change	-73.91%	7.59%	-87.5%
Acquisitions
YoY Change
Other Investing Activities	-$58.76M	$16.41M	$61.06M
YoY Change	-230.55%	36.64%	-180.96%
Cash From Investing Activities	-$58.82M	$16.16M	$61.03M
YoY Change	-231.35%	-33.73%	-180.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00	$2.248M
YoY Change			-96.61%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	13.90M	$18.55M	$2.536M
YoY Change	12536.36%	4164.14%	-95.34%
NET CHANGE
Cash From Operating Activities	-13.35M	-$23.47M	-$16.58M
Cash From Investing Activities	-58.82M	$16.16M	$61.03M
Cash From Financing Activities	13.90M	$18.55M	$2.536M
Net Change In Cash	-58.27M	$11.21M	$47.03M
YoY Change	-309.53%	-4.51%	-212.42%
FREE CASH FLOW
Cash From Operating Activities	-$13.35M	-$23.47M	-$16.58M
Capital Expenditures	-$60.00K	$255.0K	$31.00K
Free Cash Flow	-$13.29M	-$23.73M	-$16.61M
YoY Change	-21.13%	76.51%	-17.83%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	2341000	USD
CY2019Q3	abus	Accrued Payroll Current AccruedPayrollCurrent	1509000	USD
CY2018Q4	abus	Accrued Research And Development AccruedResearchAndDevelopment	2716000	USD
CY2019Q3	abus	Accrued Research And Development AccruedResearchAndDevelopment	4112000	USD
CY2018Q1	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	-504000	USD
CY2018Q2	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	-34000	USD
CY2018Q3	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	-407000	USD
CY2019Q1	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	47000	USD
CY2019Q2	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	230000	USD
CY2019Q3	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	55000	USD
CY2018Q4	abus	Employee Stock Options Liability Classified Outstanding EmployeeStockOptionsLiabilityClassifiedOutstanding	479000	USD
CY2019Q3	abus	Employee Stock Options Liability Classified Outstanding EmployeeStockOptionsLiabilityClassifiedOutstanding	86000	USD
CY2018Q3	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	-5608000	USD
	abus	Fixed Lease Cost FixedLeaseCost	900000	USD
	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	-6263000	USD
CY2019Q3	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	-376000	USD
	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	-121000	USD
CY2019Q3	abus	Lessee Operating Lease Numberof Leases LesseeOperatingLeaseNumberofLeases	2	lease
CY2019Q3	abus	Liability From Sale Of Future Royalties Additions LiabilityFromSaleOfFutureRoyaltiesAdditions	30000000	USD
CY2019Q3	abus	Liability From Sale Of Future Royalties Discounts And Issuance Costs LiabilityFromSaleOfFutureRoyaltiesDiscountsAndIssuanceCosts	11451000	USD
CY2019Q3	abus	Liability From Sale Of Future Royalties Non Cash Expense LiabilityFromSaleOfFutureRoyaltiesNonCashExpense	1106000	USD
CY2019Q3	abus	Liability From Sale Of Future Royalties Non Cash Royalty Income LiabilityFromSaleOfFutureRoyaltiesNonCashRoyaltyIncome	979000	USD
CY2019Q3	abus	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	18675000	USD
CY2019Q3	abus	Liability Related To Sale Of Future Royalties LiabilityRelatedToSaleOfFutureRoyalties	0	USD
CY2018Q4	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	0	USD
CY2019Q3	abus	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	18675000	USD
CY2018Q3	abus	Non Cash Royalty Expense Related To Sale Of Future Royalties NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties	0	USD
	abus	Non Cash Royalty Expense Related To Sale Of Future Royalties NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties	0	USD
CY2019Q3	abus	Non Cash Royalty Expense Related To Sale Of Future Royalties NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties	1106000	USD
	abus	Non Cash Royalty Expense Related To Sale Of Future Royalties NonCashRoyaltyExpenseRelatedToSaleOfFutureRoyalties	1106000	USD
CY2018Q3	abus	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	0	USD
	abus	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	0	USD
CY2019Q3	abus	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	979000	USD
	abus	Non Cash Royalty Revenue Related To Sale Of Future Royalties NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties	979000	USD
CY2018Q3	abus	Proceeds From Sale Of Future Royalties Net ProceedsFromSaleOfFutureRoyaltiesNet	0	USD
	abus	Proceeds From Sale Of Future Royalties Net ProceedsFromSaleOfFutureRoyaltiesNet	0	USD
CY2019Q3	abus	Proceeds From Sale Of Future Royalties Net ProceedsFromSaleOfFutureRoyaltiesNet	18549000	USD
	abus	Proceeds From Sale Of Future Royalties Net ProceedsFromSaleOfFutureRoyaltiesNet	18549000	USD
	abus	Strightline Fixed Lease Cost StrightlineFixedLeaseCost	900000	USD
CY2019Q3	abus	Wholly Owned Subsidiaries Includedin Financial Statements WhollyOwnedSubsidiariesIncludedinFinancialStatements	2	subsidiary
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Period End Date DocumentPeriodEndDate	2019-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001447028
CY2019Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	56850172	shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Arbutus Biopharma Corp
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Small Business EntitySmallBusiness	true
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9429000	USD
CY2019Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	8199000	USD
CY2018Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3192000	USD
CY2019Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1400000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1431000	USD
CY2019Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2488000	USD
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-128000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	871000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	48084000	USD
CY2019Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	55385000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1510000	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1862000	USD
CY2018Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1658000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1665000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3915000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1592000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	135000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24200000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28200000	shares
CY2018Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	14811000	USD
CY2019Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1177000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7090000	USD
CY2019Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8612000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48170000	USD
CY2019Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48217000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	14811000	USD
CY2019Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	43836000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	43836000	USD
CY2018Q4	us-gaap	Assets Assets	227905000	USD
CY2019Q3	us-gaap	Assets Assets	117277000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	129229000	USD
CY2019Q3	us-gaap	Assets Current AssetsCurrent	94341000	USD
CY2018Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-5608000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-6263000	USD
CY2019Q3	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-376000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-121000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	10424000	USD
CY2018Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	4161000	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3126000	USD
CY2019Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3005000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36942000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	90082000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	66893000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10193000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21933000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36942000	USD
CY2019Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	78872000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	90082000	USD
CY2018Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	11740000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-44960000	USD
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	11210000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	53140000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-82476000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4282000	USD
CY2018Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2019Q3	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55518800	shares
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56850172	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55518800	shares
CY2019Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56850172	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	879405000	USD
CY2019Q3	us-gaap	Common Stock Value CommonStockValue	884623000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-24485000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-38823000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-129116000	USD
CY2018Q3	us-gaap	Contribution Of Property ContributionOfProperty	0	USD
	us-gaap	Contribution Of Property ContributionOfProperty	24665000	USD
CY2019Q3	us-gaap	Contribution Of Property ContributionOfProperty	0	USD
	us-gaap	Contribution Of Property ContributionOfProperty	0	USD
CY2018Q3	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-4282000	USD
CY2019Q3	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-12661000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-12661000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	12661000	USD
CY2019Q3	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	USD
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	645000	USD
CY2019Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
CY2018Q3	us-gaap	Depreciation Depreciation	497000	USD
	us-gaap	Depreciation Depreciation	1677000	USD
CY2019Q3	us-gaap	Depreciation Depreciation	507000	USD
	us-gaap	Depreciation Depreciation	1521000	USD
CY2018Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	497000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1677000	USD
CY2019Q3	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	507000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1521000	USD
CY2018Q3	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	2567000	USD
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	7444000	USD
CY2019Q3	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	2792000	USD
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	8269000	USD
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.49
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.84
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.50
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.43
CY2018Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	131000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-795000	USD
CY2019Q3	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-24000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	71000	USD
CY2018Q4	us-gaap	Equity Method Investments EquityMethodInvestments	22224000	USD
CY2019Q3	us-gaap	Equity Method Investments EquityMethodInvestments	10969000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	11000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2018Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	145000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-740000	USD
CY2019Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-25000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	43000	USD
CY2018Q3	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	131000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-795000	USD
CY2019Q3	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-24000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	71000	USD
CY2018Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	24884000	USD
CY2019Q3	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	USD
	us-gaap	Gain Loss On Investments GainLossOnInvestments	0	USD
CY2018Q3	us-gaap	Gain Loss On Sale Of Equity Investments GainLossOnSaleOfEquityInvestments	-2838000	USD
	us-gaap	Gain Loss On Sale Of Equity Investments GainLossOnSaleOfEquityInvestments	-2838000	USD
CY2019Q3	us-gaap	Gain Loss On Sale Of Equity Investments GainLossOnSaleOfEquityInvestments	-3512000	USD
	us-gaap	Gain Loss On Sale Of Equity Investments GainLossOnSaleOfEquityInvestments	-11497000	USD
CY2018Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	26000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	26000	USD
CY2019Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2018Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2631000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10075000	USD
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3249000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15850000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	22471000	USD
CY2019Q3	us-gaap	Goodwill Goodwill	0	USD
CY2019Q3	us-gaap	Goodwill Goodwill	0	USD
CY2018Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019Q3	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	22471000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	22500000	USD
	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	22471000	USD
CY2018Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	14811000	USD
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	14811000	USD
CY2019Q3	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	43836000	USD
	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	43836000	USD
CY2018Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-28755000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-43093000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-95159000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-141725000	USD
CY2018Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2838000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-2838000	USD
CY2019Q3	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3512000	USD
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-11497000	USD
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4282000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4282000	USD
CY2019Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-12656000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	136000	USD
CY2019Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	957000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1057000	USD
CY2018Q3	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-2000	USD
CY2018Q3	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-12656000	USD
CY2018Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1094000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2171000	USD
CY2019Q3	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	538000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1320000	USD
CY2018Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-784000	USD
CY2019Q3	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	0	USD
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	0	USD
CY2018Q3	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-325000	USD
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2093000	USD
CY2019Q3	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2019Q3	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-446000	USD
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-541000	USD
CY2018Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-109000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1017000	USD
CY2019Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1080000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1839000	USD
CY2018Q3	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-320000	USD
	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	770000	USD
CY2019Q3	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-138000	USD
	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-917000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	43836000	USD
CY2019Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	0	USD
	us-gaap	Interest Expense InterestExpense	104000	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	1100000	USD
	us-gaap	Interest Expense InterestExpense	1114000	USD
CY2018Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	756000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2319000	USD
CY2019Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	503000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	1709000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4740000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	2039000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	598000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	581000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	677000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	657000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	188000	USD
CY2019Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3758000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-10738000	USD
CY2019Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1268000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	27671000	USD
CY2019Q3	us-gaap	Liabilities Liabilities	33640000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	227905000	USD
CY2019Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	117277000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11239000	USD
CY2019Q3	us-gaap	Liabilities Current LiabilitiesCurrent	8817000	USD
CY2018Q3	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	0	USD
	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	0	USD
CY2019Q3	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	6486000	USD
	us-gaap	Loss Contingency Loss In Period LossContingencyLossInPeriod	6486000	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	435000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	55537000	USD
CY2019Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	18549000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23564000	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	24378000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-48911000	USD
CY2019Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	16155000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	87160000	USD
CY2018Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-13204000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-50791000	USD
CY2019Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23470000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-57655000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-17429000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	3091000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-24473000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-38811000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-23251000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-23315000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-82503000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-129069000	USD
CY2018Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-27040000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-46255000	USD
CY2019Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-85295000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-137338000	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3671000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	29784000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	34013000	USD
	us-gaap	Operating Expenses OperatingExpenses	77144000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	94462000	USD
	us-gaap	Operating Expenses OperatingExpenses	135380000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-32426000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-72877000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-91401000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-130987000	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	1100000	USD
CY2019Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	3472000	USD
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2019Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	329000	USD
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2019Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3143000	USD
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4100000	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	0	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	921000	USD
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2019Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2817000	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3200000	USD
CY2019Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.089
CY2019Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y3M18D
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	309000	USD
CY2019Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-12000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-12000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	27000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-47000	USD
CY2018Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-12000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-22000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-52000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	27000	USD
CY2018Q3	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	0	USD
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	48025000	USD
CY2019Q3	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	0	USD
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	0	USD
	us-gaap	Payments For Restructuring PaymentsForRestructuring	1161000	USD
CY2018Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	237000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	911000	USD
CY2019Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	255000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	526000	USD
CY2018Q1	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	USD
CY2018Q2	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	USD
CY2018Q3	us-gaap	Preferred Stock Accretion Of Redemption Discount PreferredStockAccretionOfRedemptionDiscount	0	USD
CY2018Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	2567000	USD
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	7444000	USD
CY2019Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	2792000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3181000	USD
CY2019Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1771000	USD
CY2018Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2018Q3	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	25000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	25000	USD
CY2019Q3	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	11000	USD
CY2018Q3	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	24590000	USD
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	8269000	USD
CY2018Q4	us-gaap	Preferred Stock Including Additional Paid In Capital Net Of Discount PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount	126136000	USD
CY2019Q3	us-gaap	Preferred Stock Including Additional Paid In Capital Net Of Discount PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount	134405000	USD
CY2018Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue
CY2019Q3	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1164000	shares
CY2019Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1164000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1164000	shares
CY2019Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1164000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1164000	shares
CY2019Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1164000	shares
CY2019Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4725000	USD
CY2018Q3	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	66265000	USD
CY2019Q3	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	0	USD
	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	0	USD
CY2019Q3	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	16410000	USD
	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	87675000	USD
CY2018Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	435000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1273000	USD
CY2019Q3	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	290000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10145000	USD
CY2019Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9150000	USD
CY2018Q3	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	12001000	USD
CY2019Q3	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16566000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	46871000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17731000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	45183000	USD
	us-gaap	Restructuring Charges RestructuringCharges	4800000	USD
CY2018Q3	us-gaap	Restructuring Charges RestructuringCharges	-492000	USD
	us-gaap	Restructuring Charges RestructuringCharges	3710000	USD
CY2019Q3	us-gaap	Restructuring Charges RestructuringCharges	182000	USD
	us-gaap	Restructuring Charges RestructuringCharges	33000	USD
CY2018Q3	us-gaap	Restructuring Costs RestructuringCosts	0	USD
	us-gaap	Restructuring Costs RestructuringCosts	396000	USD
CY2019Q3	us-gaap	Restructuring Costs RestructuringCosts	0	USD
	us-gaap	Restructuring Costs RestructuringCosts	0	USD
CY2018Q4	us-gaap	Restructuring Reserve RestructuringReserve	1331000	USD
CY2019Q3	us-gaap	Restructuring Reserve RestructuringReserve	203000	USD
CY2018Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	1331000	USD
CY2019Q3	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	203000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-805221000	USD
CY2019Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-942559000	USD
CY2018Q3	us-gaap	Revenues Revenues	1587000	USD
	us-gaap	Revenues Revenues	4267000	USD
CY2019Q3	us-gaap	Revenues Revenues	3061000	USD
	us-gaap	Revenues Revenues	4393000	USD
CY2018Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1828000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5445000	USD
CY2019Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1516000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6822000	USD
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	87675000	USD
CY2019Q3	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2018Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	66265000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2248000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2477000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	103000	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	735000	USD
CY2018Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	434000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	288000	USD
CY2019Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	182473000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	232418000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	238072000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	215272000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	200234000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	181209000	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	164466000	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	83637000	USD
	us-gaap	Sublease Income SubleaseIncome	100000	USD
	us-gaap	Sublease Income SubleaseIncome	200000	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	200000	USD
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55421504	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55241284	shares
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	56850172	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	56469358	shares
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of business and future operations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus Biopharma Corporation (the “Company” or “Arbutus”) is a biopharmaceutical business dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by the hepatitis B virus (“HBV”). To pursue its strategy of developing a curative combination regimen, the Company has assembled a pipeline of multiple drug candidates with differing and complementary mechanisms of action targeting HBV. These include AB-729, the Company's subcutaneously-delivered RNA interference ("RNAi") therapeutic candidate currently in a Phase 1a/1b clinical trial, AB-452, the Company's lead oral HBV RNA destabilizer candidate currently in pre-clinical testing, next-generation oral capsid inhibitor compounds, and compounds that inhibit PD-L1. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieving profitable operations. The Company's research and development activities and commercialization of its products are dependent on its ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of the Company's existing or future research and development programs or the Company’s ability to continue to fund these programs in the future.</font></div></div>

Files In Submission

Name	View Source	Status
0001447028-19-000071-index-headers.html	Edgar Link	pending
0001447028-19-000071-index.html	Edgar Link	pending
0001447028-19-000071.txt	Edgar Link	pending
0001447028-19-000071-xbrl.zip	Edgar Link	pending
abus-20190930.xml	Edgar Link	completed
abus-20190930.xsd	Edgar Link	pending
abus-20190930_cal.xml	Edgar Link	unprocessable
abus-20190930_def.xml	Edgar Link	unprocessable
abus-20190930_lab.xml	Edgar Link	unprocessable
abus-20190930_pre.xml	Edgar Link	unprocessable
arbutusq32019.htm	Edgar Link	pending
boardagreementcheng.htm	Edgar Link	pending
boardagreementcheng001.jpg	Edgar Link	pending
exhibit311q32019.htm	Edgar Link	pending
exhibit312q32019.htm	Edgar Link	pending
exhibit321q32019.htm	Edgar Link	pending
exhibit322q32019.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
formofindemnificationagr.htm	Edgar Link	pending
formofindemnificationagr001.jpg	Edgar Link	pending
formofindemnificationagr002.jpg	Edgar Link	pending
formofindemnificationagr003.jpg	Edgar Link	pending
formofindemnificationagr004.jpg	Edgar Link	pending
formofindemnificationagr005.jpg	Edgar Link	pending
formofindemnificationagr006.jpg	Edgar Link	pending
formofindemnificationagr007.jpg	Edgar Link	pending
hbvpipeline002.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABUS
Arbutus Biopharma Corp Stock $abus

2019 Q4 Form 10-Q Financial Statement

#000144702819000071 Filed on November 06, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS Arbutus Biopharma Corp Stock $abus

2019 Q4 Form 10-Q Financial Statement

#000144702819000071 Filed on November 06, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS
Arbutus Biopharma Corp Stock $abus